Given the potential advantages of sGC activators over sGC stimulators in conditions like SSc, and supported by the presented data, a Phase II trial investigating the safety and efficacy of avenciguat in patients with SSc is ongoing (NCT05559580). The gene discussed is SGCB; the disease is systemic sclerosis.